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Abstract
Background: Rapid influenza diagnosis is important for early identification of outbreaks, effective management of
high-risk contacts, appropriate antiviral use, decreased inappropriate antibiotic use and avoidance of unnecessary
laboratory testing. Given the inconsistent performance of many rapid influenza tests, clinical diagnosis remains
integral for optimizing influenza management. However, reliable clinical diagnostic methods are not well-
established. This study assesses predictors of influenza, and its various subtypes, in a broad population at the point
of care, across age groups, then evaluates the performance of clinical case definitions composed of identified
predictors.
Methods: Respiratory specimens and demographic and clinical data were obtained from 3- to 80-year-old US
military family members presenting for care with influenza-like illness (ILI) from November 2007 to April 2008.
Molecular and virus isolation techniques were used to detect and subtype influenza viruses. Associations between
influenza diagnosis and demographic/clinical parameters were assessed by logistic regression, including influenza
type and subtype analyses. The predictive values of multiple combinations of identified clinical predictors (case
definitions), and the Centers for Disease Control and Prevention (CDC) ILI case definition, were estimated.
Results: Of 789 subjects, 220 (28%) had laboratory-confirmed influenza (51 A(H1), 46 A(H3), 19 A(unsubtypeable),
67 B, 1 AB coinfection), with the proportion of influenza A to B cases highest among 6- to 17-year-olds (p= 0.019).
Independent predictors of influenza included fever, cough, acute onset, body aches, and vaccination status among
6- to 49-year-olds, only vaccination among 3- to 5-year-olds, and only fever among 50- to 80-year-olds. Among
6- to 49-year-olds, some clinical case definitions were highly sensitive (100.0%) or specific (98.6%), but none had
both parameters over 60%, though many performed better than the CDC ILI case definition (sensitivity 37.7%, 95%
confidence interval 33.6–41.9% in total study population).
Conclusions: Patterns of influenza predictors differed across age groups, with most predictors identified among
6- to 49-year-olds. No combination of clinical and demographic predictors served as a reliable diagnostic case
definition in the population and influenza season studied. A standardized clinical case definition combined with a
point-of-care laboratory test may be the optimal rapid diagnostic strategy available.
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Background
Influenza infections result in 3–5 million illnesses
and 500,000 deaths each year worldwide [1]. The US
records an average of 226,000 hospitalizations and
36,000 deaths annually [2]. Because of high mutabil-
ity, cross-species transfer, and reservoir diversity, in-
fluenza is not considered eradicable [3–5]; effective
prevention and treatment are needed to mitigate its
impact. Prompt and accurate diagnosis facilitates early
identification of outbreaks, timely intervention, effective
management of high-risk contacts, appropriate antimicro-
bial use, and avoidance of unnecessary laboratory testing
[6]. Recent experience with pandemic H1N1 influenza
(pH1N1) [7,8] highlights the need to reevaluate current
diagnostic capabilities and seasonal influenza’s clinical
presentation.
Polymerase chain reaction (PCR) assays discriminate be-
tween influenza types and subtypes and are more sensitive
(83%–96%) than culture (44%–57%) [9–11]; PCR typically
requires up to 24 hours for results; culture can require
10 days. Rapid influenza detection tests (RIDTs) are avail-
able with high specificities (96%–100%) but poor sensitiv-
ities (27%–69%) [12–15]. Lacking rapid assays that are
consistently sensitive, a reliable model for predicting influ-
enza infection based on clinical and demographic para-
meters would be valuable.
Multiple studies have evaluated clinical case defini-
tions (clinical and demographic parameter combina-
tions) as diagnostic tools [16–30]. Interpretation and
application of these findings is hampered by differing
methodologies, disparate clinical settings, varying inclu-
sion criteria, a wide range of influenza prevalence,
multiple outcome measures, and virus evolution. Ap-
proximately half of these studies found clinical models
to predict influenza [17,18,21,23,26,27,29–31], suggest-
ing the presence of fever, cough, and acute onset
might accurately identify influenza during a local epi-
demic. Few prior studies analyzed the effect of age on
clinical predictors, although two studies suggested pre-
dictor models are age dependent [27,30]. A 2005
meta-analysis highlighted the non-standardization
problem when it found only ten of 915 studies on
symptom-based influenza diagnosis from 1966 to 2004
to meet the following criteria: (1) prospective design or
randomized trial, (2) inclusion of primary assessment of
clinical predictors of influenza, (3) use of standard
laboratory-based outcome, and (4) high study quality
based on a previously published scheme [18]. A 2011 sys-
tematic review covering a similar time frame identified 12
studies meeting similar criteria; authors found fever plus
cough and fever/cough/acute onset heuristics to have
areas under the receiver operating characteristic curves of
0.70 and 0.79, respectively. Authors additionally observe
that none of the more robust studies have conducted a
split-sample validation nor prospectively validated a clin-
ical decision rule [31].
We present findings that (1) identify influenza predic-
tors in different age groups, (2) assess the diagnostic
value of clinical case definitions based on these predic-
tors, and (3) compare clinical presentation across influ-




From November 2007 to May 2008 study personnel
recruited eligible clinic patients with subjective fever and/
or temperature >38.0 °C and either a cough or sore
throat into an ongoing laboratory-based respiratory dis-
ease surveillance study. This surveillance study was estab-
lished to track rates and etiologies of respiratory disease
in the local military dependent population, as well as to
provide an infrastructure for the evaluation of novel
influenza diagnostics. Recruitment occurred in two
community-based outpatient clinics and the emergency
department and pediatric clinic at Naval Medical Center
San Diego, all part of the regional military treatment area
serving half a million Department of Defense (DoD) cli-
ents. Eligible subjects were DoD dependents or retirees
ages 3–80 years who provided, or whose legal guardians
provided, informed consent. Though non-participation
rates could not be tracked precisely, and demographics of
non-participants are not known, it is estimated that
greater than 90% of those solicited were enrolled.
Data collected
Associates interviewed each subject/guardian to deter-
mine age, sex, presence of subjective fevers, number of
days since symptom onset, smoking history (pack-years),
vaccine history, and presence of eight symptoms during
the current illness (see Table 1). Subject temperature
(oral) was obtained from the medical record.
Specimen processing
Specimen collection and processing proceeded according
to three schemes varying by number and type of speci-
mens tested and whether they were frozen or processed
fresh. This variation resulted from concomitant evalu-
ation of two novel influenza diagnostics occurring in the
same population, the evaluations requiring different spe-
cimen combinations. Up to two mucosal respiratory spe-
cimens (throat and/or nasal swabs) were collected for
testing using Dacron swabs (Remel, Inc., MicroTest
Viral Transport Media [VTM] Female Kit, Reference
#12550) immediately placed into the VTM. When both
a nasal and throat specimen were requested, specimens
were maintained at 2–8 °C or on ice and all testing was
initiated within 72 hours of collection. All other
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Table 1 Descriptive statistics for laboratory-confirmed influenza outcomes and demographic and clinical variables
Subjects ages Subjects ages Subjects ages Subjects ages
Total study population 3–5 years 6–17 years 18–49 years 50–80 years
Variable (n=789) (n=65) (n=197) (n=326) (n=201)
Outcome variables n (%) n (%) n (%) n (%) n (%)
Influenza diagnosis
Positive 220 (27.9) 12 (18.5) 65 (33.0) 92 (28.2) 51 (25.4)
Negative 569 (72.1) 53 (81.5) 132 (67.0) 234 (71.8) 150 (74.6)
Influenza type
A 152 (69.1) 7 (58.3) 53 (81.5) 63 (68.5) 29 (56.9)
B 67 (30.5) 5 (41.7) 11 (16.9) 29 (31.5) 22 (43.1)
AB 1 (0.5) 0 (0.0) 1 (1.5) 0 (0.0) 0 (0.0)
Influenza A subtypea
H1 51 (44.0) 3 (42.9) 19 (44.2) 18 (38.3) 11 (57.9)
H3 46 (39.7) 1 (14.3) 21 (48.8) 17 (36.2) 7 (36.8)
Unsubtypeable 19 (16.4) 3 (42.9) 3 (7.0) 12 (25.5) 1 (5.3)
Continuous variables Value (error)b Value (error)b Value (error)b Value (error)b Value (error)b
Age (years) 31.2 (19.4) 4.0 (0.8) 11.5 (3.6) 32.0 (9.9) 56.8 (5.3)
Symptom duration (days) 4.0 (1–90) 4.0 (1–30) 3.0 (1–60) 5.0 (1–60) 5.0 (1–90)
Temperature (°C) 36.9 (35.6–40.3) 36.8 (35.9–39.5) 37.1 (35.6–40.3) 36.9 (35.9–39.6) 36.8 (35.6–39.3)
Smoking history (pack-years) 0.0 (0–117.5)c ––d ––d 0.0 (0–51)c 0.0 (0–117.5)
Vaccine to Onset Time (Days)e 80 (0–365) 57 (0–198) 74 (6–348) 89 (3–342) 85.4 (8–365)
Categorical variables n (%) n (%) n (%) n (%) n (%)
Enrollment site
Outpatient clinic 1 284 (36.0) 6 (9.2) 61 (31.0) 137 (42.0) 80 (39.8)
Outpatient clinic 2 203 (25.7) 15 (23.1) 55 (27.9) 63 (19.3) 70 (34.8)
Emergency room 246 (31.2) 24 (36.9) 47 (23.9) 124 (38.0) 51 (25.4)
Pediatric clinic 56 (7.1) 20 (30.8) 34 (17.3) 2 (0.6) 0 (0.0)
Sex
Female 494 (62.6) 30 (46.2) 87 (44.2) 270 (82.8) 107 (53.2)
Male 295 (37.4) 35 (53.8) 110 (55.8) 56 (17.2) 94 (46.8)
Acute onset
≤3 days 273 (34.6) 30 (46.2) 99 (50.3) 100 (30.7) 44 (21.9)
>3 days 516 (65.4) 35 (53.8) 98 (49.8) 226 (69.3) 157 (78.1)
Fever
>38.0°C 126 (16.0) 11 (16.9) 48 (24.4) 43 (13.2) 24 (11.9)
≤38.0°C 663 (84.0) 54 (83.1) 149 (75.6) 283 (86.8) 177 (88.1)
Cough
Yes 736 (93.3) 63 (96.9) 176 (89.3) 299 (91.7) 198 (98.5)
No 53 (6.7) 2 (3.1) 21 (10.7) 27 (8.3) 3 (1.5)
Sore throat
Yes 630 (79.8) 33 (50.8) 170 (86.3) 278 (85.3) 149 (74.1)
No 159 (20.2) 32 (49.2) 27 (13.7) 48 (14.7) 52 (25.9)
Shortness of breathe
Yes 346 (43.9) 20 (30.8) 73 (37.2) 166 (50.9) 87 (43.3)
No 442 (56.0) 45 (69.2) 123 (62.8) 160 (49.1) 114 (56.7)
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specimens were refrigerated for ≤10 hours after collec-
tion then stored at ≤−70 °C until testing.
Each specimen was tested for influenza A by end-point
reverse transcriptase PCR (RT-PCR) as previously
described using primer sets 2 and 2.5 [32]. Each was also
inoculated on rhesus monkey kidney cells for virus isola-
tion [33]; cultures exhibiting cytopathic effect within
14 days were tested using an indirect immunofluorescence
assay with type-specific monoclonal antibodies for viral
identification. Isolates were subtyped by hemagglutination
inhibition (HAI) using the World Health Organization In-
fluenza Reagent Kit for Identification of Influenza Isolates
2007–2008 (WHO, Geneva, Switzerland). A portion of
unsubtypeable specimens were tested with the T5000 PCR/
electrospray ionization mass spectrometer (ESI-MS) (Ibis
Pharmaceuticals, Carlsbad, CA) as previously described
[34] to identify influenza subtype.
Statistical analysis
Laboratory-confirmed influenza was defined as having
any specimen positive for influenza by RT-PCR or virus
isolation from cell culture. Influenza A status was
determined by RT-PCR and virus isolation and influenza
B status by virus isolation. An influenza A(H1) or A(H3)
case was a subject with any specimen positive for that
influenza subtype by HAI.
The study population was grouped into age categories:
3–5 years, 6–17 years, 18–49 years, and 50–80 years,
chosen based on standard clinical groupings according to
probable influenza exposure/risk environments. Age was
treated as a continuous variable within each group. Di-
chotomous variables were constructed from all clinical
parameters. Acute onset was defined as symptom onset
≤3 days before presentation. Fever was defined as
temperature >38.0 °C. Since inclusion criteria required
cough or sore throat, these two variables were not con-
sidered independent of each other; sore throat was
excluded from the multivariate model. History of ad-
equate vaccination was defined as receipt >14 and
≤365 days prior to symptom onset.
Rates of influenza across age groups were compared
using Pearson’s chi-square test. Bivariate exact condi-
tional regression was performed in each age group to
model the probability of laboratory-confirmed influenza
Table 1 Descriptive statistics for laboratory-confirmed influenza outcomes and demographic and clinical variables
(Continued)
Nasal congestion
Yes 650 (82.4) 51 (78.5) 155 (78.7) 271 (83.1) 173 (86.1)
No 139 (17.6) 14 (21.5) 42 (21.3) 55 (16.9) 28 (13.9)
Headache
Yes 619 (78.5) 31 (47.7) 134 (68.0) 286 (87.7) 168 (83.6)
No 170 (21.5) 34 (52.3) 63 (32.8) 40 (12.3) 33 (16.4)
Conjunctivitise
Yes 44 (5.6) 6 (9.2) 4 (2.0) 16 (4.9) 18 (9.0)
No 744 (94.3) 59 (90.8) 193 (98.0) 309 (94.8) 183 (91.0)
Body achese
Yes 581 (73.6) 27 (41.5) 99 (50.2) 289 (88.7) 166 (82.6)
No 207 (26.2) 37 (56.9) 98 (49.8) 37 (11.4) 35 (17.4)
Nausea/vomiting
Yes 347 (44.0) 19 (29.2) 107 (54.3) 155 (47.5) 66 (32.8)
No 442 (56.0) 46 (70.8) 90 (45.7) 171 (52.5) 135 (67.2)
Smoker
Yes 157 (19.9) 0 (0.0) 0 (0.0) 88 (27.0) 69 (34.3)
No 632 (80.1) 65 (100.0) 197 (100. 0) 238 (73.0) 132 (65.7)
Vaccinated
Yes 217 (27.5) 17 (26.2) 27 (13.7) 85 (26.1) 88 (43.8)
No 572 (72.5) 48 (73.9) 170 (86.3) 241 (73.9) 113 (56.2)
NOTE. Percentages are rounded, thus may not add up to 100%. aDenominator is subjects with at least one specimen positive by culture for influenza A.
bContinuous variable values reported as “mean (standard deviation)” if symmetric variable, or “median (low end–high end of range)” if nonsymmetric. cTwo
subjects in age group reported history of smoking but datum for number of pack-years is missing. dIn this age group no subjects reported pack-years >0.
eMedian (range) reported for subset of subjects who reported any influenza vaccine within the 12 months prior to presentation. fDatum missing for 1 subject in
study population.
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against age, sex, acute onset, fever, cough, sore throat,
shortness of breath, nasal congestion, headache, con-
junctivitis, body aches, nausea/vomiting, smoking his-
tory, and vaccination status. Age groups demonstrating
similar predictor patterns were combined and bivariate
analyses repeated. Backward stepwise logistic regression
using all above variables except sore throat was
employed to create a reduced multivariate model. Age
and sex remained in the reduced model regardless of
any association. The associations between influenza and
both enrollment site and number/type of specimens
were assessed in bivariate and multivariate models in the
whole population. Both were then removed from the
model because they did not alter predictor variable asso-
ciations. The same clinical and demographic variables
used in the primary multivariate model were evaluated
for associations with laboratory-confirmed influenza A
versus B and influenza A(H1) versus A(H3) in bivariate
and multivariate logistic regression models in the com-
bined age group.
Variables demonstrating associations with laboratory-
confirmed influenza (ie, the predictors of influenza) in
the combined age group reduced model were incorpo-
rated into various clinical case definitions classified by at
least n criteria or by particular combinations of clinical
criteria. Modeling these case definitions as diagnostic
tests, four test performance parameters—sensitivity, spe-
cificity, and positive and negative predictive values (PPV,
NPV)—were calculated. Performance of the Centers for
Disease Control and Prevention (CDC) influenza-like ill-
ness (ILI) case definition (temperature ≥37.8 °C and ei-
ther cough or sore throat) [35] was assessed for
comparison. Confidence intervals (CIs) for performance
parameters were calculated for binomial proportions.
All statistical analyses utilized SAS software, version
9.1 (SAS Institute, Inc., Cary, NC); p values< .05 were
considered significant. This study was approved by the
Naval Health Research Center Institutional Review
Board and followed the human subject research guide-
lines of that institution.
Results
Between November 14, 2007 and April 8, 2008, spanning
the local influenza season, 796 subjects were enrolled.
Six subjects withdrew before specimen collection; one
was excluded due to specimen mislabeling. The
remaining 789 subjects were analyzed; 199 provided a
throat specimen, 145 provided a nasal specimen, and
445 provided both.
Subject characteristics and outcomes are reported in
Table 1. The overall influenza prevalence was 27.9%.
Cases included 19.3% influenza A (44.0% A(H1), 39.7%
A(H3), 16.4% unsubtypeable), 8.5% influenza B, and 1
influenza A/B co-infection. Of the 19 subjects with ini-
tially unsubtypeable influenza A infections, five subjects
had sufficient remaining sample for further testing; all
five subjects were positive for influenza A(H3) by PCR/
ESI-MS (results not included in subsequent analyses).
Distribution of cases throughout the season is illustrated
in the Figure 1.
During the 2007–2008 season, laboratory-confirmed
influenza rates were highest (33.0%) among 6- to 17-year-
olds and lowest (18.5%) among 3- to 5-year-olds, though
these differences were not significant (p= .110 across all
age groups). The proportion of influenza A(H3) to A
(H1) cases did not significantly differ across age groups
(p= .623), but the proportion of influenza A to B dif-














































































































































Figure 1 Distribution of laboratory-confirmed influenza cases and overall influenza rate, during the 2007–2008 influenza season. NOTE.
Histogram depicts all laboratory-confirmed influenza cases in the study population, by type and subtype, throughout the duration of the study,
along with the percentage of subjects who were positive for any influenza type by week.
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duration ≥30 days (n=14) had laboratory-confirmed in-
fluenza; 14 of 66 (21.2%) subjects reporting symptom
duration of 14–29 days had influenza. Two subjects
(0.3%), one influenza positive, denied a subjective fever
and were eligible based solely on their recorded tem-
peratures >38.0 °C; 577 subjects (73.1%) had both a
cough and sore throat.
Laboratory-confirmed influenza rates varied from
21.2% at outpatient clinic 2 to 38.2% in the emergency
room (p= .043 in multivariate model). Subjects contrib-
uting only one nasal specimen had a significantly lower
rate of laboratory-confirmed influenza (17.9%) compared
with those contributing one throat specimen only
(29.7%) and one of each (30.3%) (p= .011 in multivariate
model).
Bivariate regression revealed significant associations
between laboratory-confirmed influenza and acute onset,
fever, cough, body aches, and unvaccinated status in the
whole population, 6- to 17-year-olds and 18- to 49-year-
olds. These latter two age groups were subsequently
combined due to these similarities (Table 2). Among
50- to 80-year-olds, only fever was predictive; in 3- to
5-year-olds, only unvaccinated status was predictive.
Multiple logistic regression in 6- to 49-year-olds
showed the same pattern of associations with laboratory-
confirmed influenza as bivariate analyses (Table 3). Nei-
ther enrollment site nor number and type of specimens
tested altered the association between clinical predictors
of interest and laboratory-confirmed influenza.
Table 4 displays the performance of 15 clinical case
definitions as diagnostic tests constructed from combi-
nations of acute onset, fever, cough, and body aches in
6- to 49-year-olds. Vaccination was not included given
its variable clinical significance over influenza seasons.
The highest specificity (98.6%) was noted with the all-
4-criteria test; however, the sensitivity was 14.6%. The
at-least-2-criteria test had a sensitivity of 94.9%, but a
specificity of 20.2% and PPV of 33.8%. The CDC ILI case
definition was most sensitive (50.8%, not shown) with
the highest PPV (57.9%) among 6- to 17-year-olds and
least sensitive among 3- to 5-year-olds (25.0%).
Bivariate logistic regression modeling of influenza B
versus A in 6- to 49-year-olds (n = 156) revealed signifi-
cant or borderline associations with age, smoking, acute
onset, fever, and vaccination. In multiple logistic regres-
sion modeling positive smoking history was associated
with increased odds of influenza A versus B (adjusted
odds ratio [OR], 8.95; 95% CI, 1.99–40.24). Age in
1-year units (OR, 1.07; 95% CI, 1.03–1.11) and vacci-
nated status (OR, 4.51; 95% CI, 1.19–17.09) were asso-
ciated with influenza B versus A. Bivariate modeling of
influenza A(H3) versus A(H1) in the same age group
(n = 75) demonstrated no significant differences. How-
ever, the multivariate model demonstrated an association
between positive smoking history and influenza A(H3)
(OR, 10.47; 95% CI, 1.28–85.46) and fever associated
with influenza A(H1) (OR, 4.48; 95% CI, 1.11–18.12).
Discussion
This study compared the predictive values of demo-
graphic and clinical factors for laboratory-confirmed in-
fluenza during the 2007–2008 influenza season in
Southern California among different age groups and
evaluated the performance of resulting case definitions.
Marked variations across age groups were found with
robust predictors among 6- to 49-year-olds and few pre-
dictors among younger children and older adults. No
single case definition was found to have both a sensitiv-
ity and specificity of clinical utility, even in an age group
exhibiting the strongest predictors; the CDC ILI case
definition would have excluded 62% of influenza cases in
this study population. With no evidence for a diagnostic-
ally useful case definition (used alone) and the potential
unreliability of RIDTs [12,36], new diagnostic strategies
are urgently needed.
In our study population, 6- to 49-year-olds had the high-
est influenza rate (differences not statistically significant),
with strong associations found between laboratory-
confirmed influenza and acute onset, fever, cough, body
aches, and unvaccinated status, consistent with prior stud-
ies [16,17,21,23,25,37]. Cough had the strongest associ-
ation with influenza. Influenza positive 6- to 49-year-olds
had approximately three times the odds of being unvac-
cinated (n=141, 89.8%) compared to negative subjects
(n=270, 73.8%) (p= .001), suggesting a moderate protect-
ive effect of the vaccine for this season in this age group.
No demographic or clinical predictors of influenza were
found among 3- to 5-year-olds, consistent with findings in
similar studies [27]. The difficulty of eliciting a symptom-
atic history when the subject has limited language skills
may contribute to this phenomenon [38]. Vaccination
appeared strongly protective in this age group. A (non-
significant) lower rate of influenza in this group conflicts
with the common belief that young children exhibit a
higher incidence of influenza, higher viral loads and
higher persistence of the virus. However, CDC data from
outpatients with ILI in 12 states during the 2010–2011 in-
fluenza season suggests that the rate of laboratory-
confirmed influenza was lower among children< 5 years
old compared to 5- to 17-year-olds [39]. Among 50- to
80-year-olds, only fever was associated with influenza,
consistent with prior studies failing to identify reliable
clinical predictors among older adults [20,24]. No protect-
ive effect from vaccination was apparent in this group, as
might be expected with age-related waning immunity
[40], although denominators were small.
Together, these findings substantiate previous observa-
tions that during a community influenza epidemic, acute
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Table 2 Bivariate regression analysis of laboratory-confirmed influenza versus seven demographic and clinical variables of interest
Variable Laboratory-confirmed influenza diagnosis
Total study population Subjects ages 3–5 years Subjects ages 6–49 years Subjects ages 50–80 years
(n=789) (n=65) (n=523) (n=201)
n/total (%)a OR (95% CI) n/total (%)a OR (95% CI) n/total (%)a OR (95% CI) n/total (%)a OR (95% CI)
Continuous variable
Age (years) 1.00 (0.99–1.01) 0.47 (0.17–1.10) 0.99 (0.98–1.01) 1.01 (0.95–1.07)
Categorical variables
Sex
Female 141/494 (28.5) 1.09 (0.78–1.53) 5/30 (16.7) 0.80 (0.18–3.38) 109/357 (30.5) 1.08 (0.71–1.66) 27/107 (25.2) 0.98 (0.50–1.96)
Maleb 79/295 (26.8) 1.0 7/35 (20.0) 1.0 48/166 (28.9) 1.0 24/94 (25.5) 1.0
Acute onset
≤3 days 110/273 (40.3) 2.49 (1.78–3.48) 8/30 (26.7) 2.77 (0.65–14.21) 86/199 (43.2) 2.71 (1.81–4.06) 16/44 (36.4) 1.98 (0.90–4.31)
>3 daysb 110/516 (21.3) 1.0 4/35 (11.4) 1.0 71/324 (21.9) 1.0 35/157 (22.3) 1.0
Fever
> 38.0°C 65/126 (51.6) 3.49 (2.31–5.27) 1/11 (9.1) 0.40 (0.01–3.37) 51/91 (56.0) 3.91 (2.39–6.44) 13/24 (54.2) 4.28 (1.63–11.51)
≤ 38.0°Cb 155/663 (23.4) 1.0 11/54 (20.4) 1.0 106/432 (24.5) 1.0 38/177 (21.5) 1.0
Cough
Yes 219/736 (29.8) 22.99 (3.72–890.52) 12/63 (19.0) 0.55 (≥0.04) c 156/475 (32.8) 22.92 (3.84–932.74) 51/198 (25.8) 1.32 (≥0.14) c
Nob 1/53 (1.9) 1.0 0/2 (0.0) 1.0 1/48 (2.1) 1.0 0/3 (0.0) 1.0
Body achesd
Yes 177/581 (30.5) 1.67 (1.13–2.50) 8/27 (29.6) 3.40 (0.79–17.59) 127/388 (32.7) 1.70 (1.06–2.79) 42/166 (25.3) 0.98 (0.40–2.57)
Nob 43/207 (20.8) 1.0 4/37 (10.8) 1.0 30/135 (22.2) 1.0 9/35 (25.7) 1.0
Vaccinated
Yes 39/217 (18.0) 0.47 (0.31–0.71) 0/17 (0.0) 0.13 (≤0.89) c 16/112 (14.3) 0.32 (0.17–0.57) 23/88 (26.1) 1.07 (0.54–2.13)
Nob 181/572 (31.6) 1.0 12/48 (25.0) 1.0 141/411 (34.3) 1.0 28/113 (24.8) 1.0
NOTE. Bivariate exact conditional logistic regression was performed in each age group. Bivariate results (OR, odds ratio; CI, confidence interval) are displayed here for all variables of interest (those that were retained in
the final multivariate regression model in any age group) modeled against laboratory-confirmed influenza. aNumber of subjects meeting criteria at left who have laboratory-confirmed influenza/all subjects meeting




















onset of fever and cough in young to middle-aged adults
are the best individual clinical predictors for laboratory-
confirmed influenza [17,21], with young children dem-
onstrating the fewest predictors [27]. Differing influenza
detection rates according to specimen type collected
warrants further study.
The all-4-criteria clinical case definition (requiring
acute onset, fever, cough, and body aches) had a strong
specificity among 6- to 49-year-olds (98.6%), but missed
85% of influenza cases. The at-least-2-criteria test (sub-
ject must have at least two of the four criteria) captured
94.9% of cases, but only excluded influenza in 20.2% of
noncases; 33.8% of test positives had influenza in this
group (overall prevalence similar to that of a typical in-
fluenza epidemic). The clinical tests defined by exactly
two or three criteria likewise performed poorly, though
roughly half had higher sensitivity than the CDC ILI
case definition (40.1%) in this age group. The CDC ILI
definition’s sensitivity varied significantly across age
groups, with the poorest performance among 3- to 5-
year-olds and the highest among 6- to 49-year-olds.
Across the whole population the CDC ILI definition
missed >60% of cases and had a PPV <60% in each age
group. NPVs ranged from 73-100%, indicating that the
absence of most of the symptoms modeled effectively
predicted the absence of influenza infection; the at-least-
1-criterion test, at-least-2-criteria test, and “cough+ any
of other 3 criteria” test could all be utilized to exclude
influenza (NPV >90%), eliminating the need for a
follow-up rapid or laboratory-based test.
All case definitions in Table 4 performed inferiorly to
the typically cited sensitivities (50%–70%) or specificities
(90%–95%) or both of RIDTs [36]. However, a common
RIDT was found to have a sensitivity as low as of 27%
(95% CI, 19%–32%) for influenza during 2007–2008
[12]; recent studies of that same and other RIDTs report
sensitivities 38%–69% in detection of pH1N1 [13–15]
and 31%–63% against other strains [14]. If RIDTs are
less sensitive than previously cited, their optimal diag-
nostic utility might be among groups with higher influ-
enza prevalence (eg, patients meeting a sensitive clinical
case definition like the at-least-2-criteria clinical test
during a local epidemic) with confirmatory testing fol-
lowing negative RIDT results [36].
Vaccination status was excluded in this diagnostic
modeling since the effect of vaccination is likely to
change annually with variable strain matching. Clinicians
should take vaccination status into account when mak-
ing a clinical diagnosis only once the performance of the
vaccine has been established for that region and season.
Influenza type/subtype analysis yielded unexpected
results. The meaning of the associations of influenza A
with history of smoking and influenza B with increasing
age is not clear. Researchers previously reported the two
influenza types might infect different age groups at dif-
ferent rates, but may cause a similar clinical syndrome
across age groups [22]. Differences in rates across age
groups may be related to previous circulation of similar
strains. Smoking increases with age among 6- to
49-year-olds; thus confounding is unlikely. Fever was
associated with influenza A(H1) infection compared with
A(H3). If fever correlates with a higher viral titer, it is not
surprising that the initially unsubtypeable specimens
were A(H3)-positive. However, if fever reflects more se-
vere or systemic disease, this finding contradicts previous
reports suggesting influenza A(H3) was associated with
such illness [16,41]. We are unaware of a physiologic
mechanism through which smoking would increase
the risk of influenza A(H3), or decrease the risk of
A(H1), which our results suggest, but this merits further
investigation.
This study’s major strengths include a methodology fa-
cilitating comparison to similar studies and inclusion in
meta-analyses and an analysis of age group and influenza
type/subtype effects. The surveillance population studied
Table 3 Multivariate regression of laboratory-confirmed
influenza versus demographic and clinical variables for
subjects 6–49 years
Variable β estimate OR (95% CI) p value
Intercept term −5.85 <.001




Acute onset 1.18 <.001














NOTE. CI, confidence interval; OR, odds ratio. Multivariate stepwise logistic
regression was performed in the combined age group (n= 521). The reduced
model is presented here (n= 523). Age and sex were retained in the final
model despite not being statistically associated with the outcome. aReference
category in regression model.
Woolpert et al. BMC Infectious Diseases 2012, 12:129 Page 8 of 11
http://www.biomedcentral.com/1471-2334/12/129
Table 4 Performance metrics of influenza clinical case definitions in subjects 6–49 years (n=523)
Laboratory influenza
Clinical test diagnosis
Clinical test result Positive Negative SN (%) (95% CI) SP (%) (95% CI) PPV (%) (95% CI) NPV (%) (95% CI)
At least 1 criteriona Positive 157 363 100.0 (undefined) b 0.8 (0.0–1.6) 30.2 (26.3–34.1) 100.0 (undefined) b
Negative 0 3
At least 2 criteriaa Positive 149 292 94.9 (93.0–96.8) 20.2 (16.8–23.7) 33.8 (29.7–37.8) 90.2 (87.7–92.8)
Negative 8 74
At least 3 criteriaa Positive 91 73 58.0 (53.7–62.2) 80.1 (76.6–83.5) 55.5 (51.2–59.7) 81.6 (78.3–84.9)
Negative 66 293
All 4 criteriaa Positive 23 5 14.6 (11.6–17.7) 98.6 (97.6–99.6) 82.1 (78.9–85.4) 72.9 (69.1–76.7)
Negative 134 361
Exact 2 criteriac
Acute onset and fever Positive 31 22 19.7 (16.3–23.2) 94.0 (92.0–96.0) 58.5 (54.3–62.7) 73.2 (69.4–77.0)
Negative 126 344
Acute onset and cough Positive 86 85 54.8 (50.5–59.0) 76.8 (73.2–80.4) 50.3 (46.0–54.6) 79.8 (76.4–83.3)
Negative 71 281
Acute onset and body aches Positive 64 68 40.8 (36.6–45.0) 81.4 (78.1–84.8) 48.5 (44.2–52.8) 76.2 (72.6–79.9)
Negative 93 298
Fever and cough Positive 51 29 32.5 (28.5–36.5) 92.1 (89.8–94.4) 63.8 (59.6–67.9) 76.1 (72.4–79.7)
Negative 106 337
Fever and body aches Positive 42 25 26.8 (23.0–30.5) 93.2 (91.0–95.3) 62.7 (58.5–66.8) 74.8 (71.1–78.5)
Negative 115 341
Cough and body aches Positive 126 224 80.3 (76.8–83.7) 38.8 (34.6–43.0) 36.0 (31.9–40.1) 82.1 (78.8–85.4)
Negative 31 142
Cough+ any of other 3 criteria Positive 149 264 94.9 (93.0–96.8) 27.9 (24.0–31.7) 36.1 (32.0–40.2) 92.7 (90.5–95.0)
Negative 8 102
Exact 3 criteriac
Acute onset, fever, cough Positive 31 14 19.7 (16.3–23.2) 96.2 (94.5–97.8) 68.9 (64.9–72.9) 73.6 (69.9–77.4)
Negative 126 352
Acute onset, cough, body aches Positive 64 47 40.8 (36.6–45.0) 87.2 (84.3–90.0) 57.7 (53.4–61.9) 77.4 (73.8–81.0)
Negative 93 319
Acute onset, fever, body aches Positive 23 9 14.6 (11.6–17.7) 97.5 (96.2–98.9) 71.9 (68.0–75.7) 72.7 (68.9–76.5)
Negative 134 357
Fever, cough, body aches Positive 42 18 26.8 (23.0–30.5) 95.1 (93.2–96.9) 70.0 (66.1–74.0) 75.2 (71.5–78.9)
Negative 115 348
CDC ILI case definitiond
Total study population Positive 83 82 37.7 (33.6–41.9) 85.6 (82.6–88.6) 50.3 (46.0–54.6) 78.0 (74.5–81.6)
Negative 137 487
Subjects ages 3–5 years Positive 3 15 25.0 (21.3–28.7) 71.7 (67.8–75.6) 16.7 (13.4–19.9) 80.9 (77.5–84.2)
Negative 9 38
Subjects ages 6–49 years Positive 63 52 40.1 (35.9–44.3) 85.8 (82.8–88.8) 54.8 (50.5–59.0) 77.0 (73.4–80.6)
Negative 94 314
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provides an ideal setting for this analysis: a large out-
patient population at the point of care, wide age range
and socioeconomic spectrum, broad and uniform inclu-
sion criteria (resulting in symptomatic diversity), and
robust laboratory influenza diagnosis with type and sub-
type. Type distributions were similar to national (71% in-
fluenza A and 29% influenza B) [35] and local [42] rates
in the same season. The military dependent population
studied is similar to the general US population, though
dependents may be healthier due to universal access to
medical care.
Study limitations include omission of subjects ages
<3 years and incomplete data on prior vaccination his-
tory in children—potential receipt of two doses in indivi-
duals ages ≤8 years was not documented. Other
limitations include use of self-reported vaccination data,
lack of antiviral or antipyretic use history, lack of infor-
mation regarding comorbid conditions that increase risk
of influenza or adverse outcomes from influenza, and
asymmetry between influenza A and B testing methods.
Subjects in this study may not be considered high risk
for influenza complications, thus may not represent the
population for whom antiviral therapy is clearly indi-
cated for treatment of influenza infection. Clinical pre-
dictors of influenza and the performance of clinical case
definitions may differ in a high risk population. An
RT-PCR assay for influenza B was not utilized, thus true
influenza B and overall influenza rates may be underes-
timated. We believe underdiagnosis of influenza B is
more likely to create a type II error. As the clinical case
definitions modeled here were created utilizing our en-
tire data set, sensitivities and specificities could be over-
estimates of the true values; these models should be
evaluated and validated in other populations and during
other time periods. Last, we report on only one influ-
enza season and cannot assess clinical disease variations
over time resulting from antigenic drift.
Conclusions
This study demonstrates that clinical parameters
strongly predict influenza in a diverse local population
and are age-dependent; but clinical case definitions used
alone, including the CDC ILI case definition, may not
sufficiently distinguish influenza from non-influenza
during an epidemic. Case definitions could still augment
diagnosis and management for 6- to 49-year-old patients
during an influenza season: (1) screening with a sensitive
case definition followed by RIDT or definitive testing
when positive or (2) screening otherwise healthy outpati-
ents with a specific case definition. These strategies
could enhance appropriate antimicrobial use. As always,
the effect of varying seasonal and geographic rates on
diagnostic predictive values should be considered. The
2009 emergence of pH1N1 highlights the urgent need
for reevaluation of RIDTs and further investigation into
the changing clinical disease spectrum of seasonal and
novel influenza strains. An evaluation of clinical case
definitions in high-risk groups, more likely to benefit
from antiviral therapy, is needed. Standardization of clin-
ical case definitions and clinical sampling techniques
would facilitate better comparisons between studies and
more effective evaluation of influenza diagnostics.
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